Logo

LumiraDx to Publicly Offer 40M Shares

Jul 19, 2022 | staff reporter

NEW YORK – LumiraDx announced on Tuesday that it has commenced an underwritten public offering of 40 million common shares. 

The London-based firm also intends to grant the underwriters a 30-day option to buy up to an additional 6 million common shares at the public offering price, it said in a statement. Goldman Sachs, Evercore ISI, SVB Securities, and Raymond James are acting as joint bookrunning managers for the proposed offering.

LumiraDx said it expects to use the funds from the offering, along with its existing cash and cash equivalents, primarily for general corporate purposes, such as working capital for research and development, business development, and sales and marketing activities. 

In early morning trading on Tuesday, shares of the company were down about 10 percent to $2.22 on the Nasdaq.

Filed under

Business News
LumiraDx
stock offering
Europe
North America
Breaking News
The Scan

Machine Learning Helps ID Molecular Mechanisms of Pancreatic Islet Beta Cell Subtypes in Type 2 Diabetes

The approach helps overcome limitations of previous studies that had investigated the molecular mechanisms of pancreatic islet beta cells, the authors write in their Nature Genetics paper.

Culture-Based Methods, Shotgun Sequencing Reveal Transmission of Bifidobacterium Strains From Mothers to Infants

In a Nature Communications study, culture-based approaches along with shotgun sequencing give a better picture of the microbial strains transmitted from mothers to infants.

Microbial Communities Can Help Trees Adapt to Changing Climates

Tree seedlings that were inoculated with microbes from dry, warm, or cold sites could better survive drought, heat, and cold stress, according to a study in Science.

A Combination of Genetics and Environment Causes Cleft Lip

In a study published in Nature Communications, researchers investigate what combination of genetic and environmental factors come into play to cause cleft lip/palate.